PERSEVERE (BRE18-334) Clinical Trial

Triple Negative Breast Cancer (TNBC) is an aggressive form of breast cancer that makes up approximately 10-15% of all breast cancers. ER, PR, and HER2 receptors can be overexpressed in some breast cancers and then can be targeted with specific drugs. These receptors are not found in the cancer cells of patients diagnosed with TNBC, meaning there are no targeted treatments for TNBC. PERSEVERE is a clinical trial which aims to compare treatments that are personalized for patients with treatments that are considered "standard," or treatments that are generally prescribed when dealing with a specific cancer. The ultimate goal of this trial is to gain knowledge about better treatment options for people affected by TNBC. As an intern, one of my major roles is to educate the public about PERSEVERE, as well as inform them about the clinical trial process in general using social media. The goal of increasing knowledge about clinical trials is to make patients more comfortable about them and aware of trials that they, or their loved ones, could potentially participate in.